

Resource Summary Report

Generated by [RRID](#) on Aug 12, 2026

[NCCN](#)

RRID:SCR_012959

Type: Tool

Proper Citation

NCCN (RRID:SCR_012959)

Resource Information

URL: <http://www.nccn.org/>

Proper Citation: NCCN (RRID:SCR_012959)

Description: A not-for-profit alliance of 23 cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

Synonyms: National comprehensive cancer network

Resource Type: data or information resource, topical portal, portal, disease-related portal

Resource Name: NCCN

Resource ID: SCR_012959

Alternate IDs: nlx_156880

Record Creation Time: 20220129T080313+0000

Record Last Update: 20260812T044241+0000

Ratings and Alerts

No rating or validation information has been found for NCCN.

No alerts have been found for NCCN.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 691 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Jin A, et al. (2026) 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPSS2) is a potential diagnostic and prognostic biomarker in colon adenocarcinoma. Scientific reports, 16(1), 5655.

Mack M, et al. (2026) Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma. Pediatric blood & cancer, 73(3), e70122.

Sabando B, et al. (2026) A Multicenter Survival Analysis of Adults Type B-Acute Lymphoblastic Leukemia in Ecuador. A Retrospective Study of the Real World. Cancer medicine, 15(3), e71625.

Wang X, et al. (2026) Cancer Genetic Predisposition and Clinical Applications-A Narrative Review on Germline Genetic Testing, High-Risk Cancer Surveillance and Management. Genes, 17(6).

Wei XS, et al. (2026) Data tells the truth: A Knowledge distillation method for genomic survival analysis by handling censoring. Fundamental research, 6(1), 432.

Nemzoff C, et al. (2026) Cost-effectiveness of cancer interventions in Rwanda: literature review and expert elicitation for health benefits package design. BMJ public health, 4(1), e003718.

Gruber LJ, et al. (2026) Refusal of Guideline-Recommended Adjuvant Therapy in Oral Squamous Cell Carcinoma Is Associated with Less Favorable Survival Outcomes. Cancers, 18(11).

Presant CA, et al. (2026) Personal pathways to success: an innovative program to overcome cancer patient barriers to tobacco cessation and promote patient participation. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 34(7).

Nayak P, et al. (2026) Utility of quantitative pathologic analysis of pT1 colorectal carcinomas to improve prediction of lymph node metastasis. Virchows Archiv : an international journal of pathology, 488(6), 1319.

Keetley HM, et al. (2026) How often do oncologists receive industry payments from competing companies? The oncologist, 31(3).

Wang Y, et al. (2026) EGFR p.V774M/p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC- and Furmonertinib-Based Treatment: A Case Report. Cancer reports (Hoboken, N.J.), 9(1), e70444.

Cao A, et al. (2026) Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer. *JNCI cancer spectrum*, 10(1).

Sloan H, et al. (2026) Distress Screening in a Cancer Survivorship Clinic: Impact on Psychosocial Referrals. *Journal of the advanced practitioner in oncology*, 1.

Yang Z, et al. (2026) Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study. *Cancer medicine*, 15(6), e71987.

Freyer DR, et al. (2026) Survival Outcomes with Guideline-Concordant Pediatric-Inspired Regimens in Adolescent/Young Adult Acute Lymphoblastic Leukemia: Retrospective Real-World Analysis. *Drugs - real world outcomes*, 13(1), 73.

Forte G, et al. (2026) Deciphering the Causative Role of a Novel APC Gene Variant in Attenuated Familial Adenomatous Polyposis Using Germline DNA-RNA Paired Testing. *Biomedicines*, 14(1).

He C, et al. (2026) A Brand-New Drainage Fluid Predictor, ICAM-1 for Implant Loss After the Immediate Reconstruction of Breast. *Breast cancer (Dove Medical Press)*, 18, 585358.

Gadomski SJ, et al. (2026) Compliance of Dermatology Screening Visits Among Patients With Skin Cancer-Predisposing Pathogenic Variants. *JEADV clinical practice*, 5(1), 132.

He S, et al. (2026) Artificial intelligence chatbots in response to patient's common inquiries about chordoma: A cross-sectional study. *Brain & spine*, 6, 106109.

Alekhina N, et al. (2026) Real-world management and outcomes of immune-mediated diarrhea and colitis: gaps in guideline adherence and opportunities for implementation. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 34(4).